3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
11
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
NSCLC
1
Melanoma
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
pembrolizumab
15
Cisplatin
7
Cetuximab
5
dostarlimab
3
Surveys and Questionnaires
3
Carboplatin
3
fludarabine
2
abemaciclib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Nivolumab
2
Interviews as Topic
2
Fulvestrant
2
Docetaxel
2
Cyclophosphamide
2
Blood Specimen Collection
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
ribociclib
1
repotrectinib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nimotuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
osimertinib
×
30 days
×
Clear all
NCT05647122
2026-05-11
EGRET
AstraZeneca
Phase 1
Recruiting
403 enrolled